209 related articles for article (PubMed ID: 28535716)
1. Extended two-stage adaptive designs with three target responses for phase II clinical trials.
Kim S; Wong WK
Stat Methods Med Res; 2018 Dec; 27(12):3628-3642. PubMed ID: 28535716
[TBL] [Abstract][Full Text] [Related]
2. Minimax and admissible adaptive two-stage designs in phase II clinical trials.
Shan G; Zhang H; Jiang T
BMC Med Res Methodol; 2016 Aug; 16():90. PubMed ID: 27485595
[TBL] [Abstract][Full Text] [Related]
3. Optimal adaptive two-stage designs for early phase II clinical trials.
Shan G; Wilding GE; Hutson AD; Gerstenberger S
Stat Med; 2016 Apr; 35(8):1257-66. PubMed ID: 26526165
[TBL] [Abstract][Full Text] [Related]
4. Optimal futility stopping boundaries for binary endpoints.
Freitag MM; Li X; Rauch G
BMC Med Res Methodol; 2024 Mar; 24(1):80. PubMed ID: 38539108
[TBL] [Abstract][Full Text] [Related]
5. A new adaptive design based on Simon's two-stage optimal design for phase II clinical trials.
Jin H; Wei Z
Contemp Clin Trials; 2012 Nov; 33(6):1255-60. PubMed ID: 22772088
[TBL] [Abstract][Full Text] [Related]
6. Optimal adaptive two-stage designs for phase II cancer clinical trials.
Englert S; Kieser M
Biom J; 2013 Nov; 55(6):955-68. PubMed ID: 23868324
[TBL] [Abstract][Full Text] [Related]
7. Adaptive two-stage designs in phase II clinical trials.
Banerjee A; Tsiatis AA
Stat Med; 2006 Oct; 25(19):3382-95. PubMed ID: 16479547
[TBL] [Abstract][Full Text] [Related]
8. Optimal and minimax three-stage designs for phase II oncology clinical trials.
Chen K; Shan M
Contemp Clin Trials; 2008 Jan; 29(1):32-41. PubMed ID: 17544337
[TBL] [Abstract][Full Text] [Related]
9. Stochastically curtailed phase II clinical trials.
Ayanlowo AO; Redden DT
Stat Med; 2007 Mar; 26(7):1462-72. PubMed ID: 16900560
[TBL] [Abstract][Full Text] [Related]
10. Re-formulating Gehan's design as a flexible two-stage single-arm trial.
Grayling MJ; Mander AP
BMC Med Res Methodol; 2019 Jan; 19(1):22. PubMed ID: 30691398
[TBL] [Abstract][Full Text] [Related]
11. Reasonable two-stage adaptive designs for single-arm phase II clinical trials.
Kashiwabara K; Matsuyama Y
Pharm Stat; 2018 Nov; 17(6):770-780. PubMed ID: 30168250
[TBL] [Abstract][Full Text] [Related]
12. Statistical inference for extended or shortened phase II studies based on Simon's two-stage designs.
Zhao J; Yu M; Feng XP
BMC Med Res Methodol; 2015 Jun; 15():48. PubMed ID: 26048655
[TBL] [Abstract][Full Text] [Related]
13. Adaptive designs for single-arm phase II trials in oncology.
Englert S; Kieser M
Pharm Stat; 2012; 11(3):241-9. PubMed ID: 22411839
[TBL] [Abstract][Full Text] [Related]
14. Modified Simon's minimax and optimal two-stage designs for single-arm phase II cancer clinical trials.
Kim J; Schell MJ
Oncotarget; 2019 Jul; 10(42):4255-4261. PubMed ID: 31303960
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of two-stage designs of Phase 2 single-arm trials in glioblastoma: a systematic review.
Yoo W; Kim S; Garcia M; Mehta S; Sanai N
BMC Med Res Methodol; 2022 Dec; 22(1):327. PubMed ID: 36550391
[TBL] [Abstract][Full Text] [Related]
16. Point estimation and p-values in phase II adaptive two-stage designs with a binary endpoint.
Kunzmann K; Kieser M
Stat Med; 2017 Mar; 36(6):971-984. PubMed ID: 28028823
[TBL] [Abstract][Full Text] [Related]
17. Randomized phase II trials with a prospective control.
Jung SH
Stat Med; 2008 Feb; 27(4):568-83. PubMed ID: 17573688
[TBL] [Abstract][Full Text] [Related]
18. Balanced two-stage designs for phase II clinical trials.
Ye F; Shyr Y
Clin Trials; 2007; 4(5):514-24. PubMed ID: 17942467
[TBL] [Abstract][Full Text] [Related]
19. Optimal three-stage designs for phase II cancer clinical trials.
Chen TT
Stat Med; 1997 Dec; 16(23):2701-11. PubMed ID: 9421870
[TBL] [Abstract][Full Text] [Related]
20. Optimal two-stage designs allowing flexibility in number of subjects for phase II clinical trials.
Masaki N; Koyama T; Yoshimura I; Hamada C
J Biopharm Stat; 2009 Jul; 19(4):721-31. PubMed ID: 20183436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]